- Modest evidence of efficacy: Small trials and cohorts report ~40%–80% PASI reductions, especially in patients with obesity or type 2 diabetes.
- Inconsistent clinical results: The only placebo-controlled randomized trial showed no significant PASI improvement despite weight loss.
- Dual mechanism: Benefits may reflect both metabolic effects (weight loss, insulin sensitivity) and direct immunomodulation (reduced inflammatory cytokines and immune cell activity).
- Generally favorable safety and compatibility: GLP-1 RAs are well tolerated and can be coadministered with common systemic psoriasis therapies.
- Not yet established for psoriasis: Use remains adjunctive and off-label pending larger randomized clinical trials and broader evidence beyond metabolically comorbid populations.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
